|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||44.18 - 44.57|
|52-week range||39.42 - 50.65|
|PE ratio (TTM)||10.16|
|Forward dividend & yield||1.64 (3.68%)|
|1y target est||49.50|
Should Investors Be Interested in Vertex Pharmaceuticals in 2018? On October 25, 2017, Vertex Pharmaceuticals (VRTX) announced positive top-line results from its open-label Phase 3 trial that evaluated Orkambi in 60 children suffering with cystic fibrosis (or CF) who have two copies of the F508del mutation. The trial reached its primary endpoint of safety, and Orkambi demonstrated improvement in secondary endpoints such as nutritional status and sweat chloride.
Co-founder John Hood leveraged the blood-disease therapy after finding that safety concerns that had clouded its future were largely overblown.
Regeneron (REGN) and partner Sanofi announced that they will expand their investment for the development cemiplimab in oncology, and label expansion of dupilumab in Type II allergic diseases.
France's Sanofi (SASY.PA) and U.S Regeneron (REGN.O) said on Monday they would inject an additional $1 billion in the development of cemiplimab, an antibody that could, if successful, be used to treat a wide range of cancers. In a statement, the two companies said they would also accelerate the co-development of dupilumab, a "multi-targeting" drug approved in the United States and Europe to treat eczema and undergoing tests to help treat asthma, nasal polyps, eosinophilic esophagitis and food allergies. "The investment in cemiplimab will be increased to $1.64 billion, an increase of approximately $1 billion over the initial 2015 agreement and Sanofi and Regeneron will continue to equally fund cemiplimab development," the two groups said.
In December 2017, the U.S. FDA (Food and Drug Administration) approved Novo Nordisk’s (NVO) Ozempic as an addition to diet and exercise for the improvement of blood sugar levels in individuals with type ...
Alnylam (ALNY) and Sanofi entered into a strategic restructuring of their RNAi therapeutics rare genetic diseases alliance.
Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs Companies also announce submission ...
January 8, 2018 - Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will accelerate and expand investment for the clinical development of the PD-1 (programmed cell death protein 1) antibody cemiplimab in oncology and dupilumab in Type 2 allergic diseases. Both of these breakthrough therapies have the potential to benefit a number of different patient populations and this strategic investment will enable the companies to evaluate cemiplimab and dupilumab in broad clinical development programs.
APEIRON Biologics AG, a company focused on cancer immunotherapy, and Evotec AG (Frankfurt Stock Exchange:EVT) (TecDAX) (ISIN:DE0005664809) announced today that the companies received the first milestone payment from Sanofi under a 3-party alliance signed in August 2015. The milestone payment of € 3 million will be split equally between the two biotech companies. The success payment was triggered when the partners successfully advanced an undisclosed, novel, immuno-oncology small molecule into late-stage pre-clinical development.
Sanofi’s recent disclosure of safety problems with the world’s only approved vaccine against the dengue has complicated efforts to contain a growing global epidemic, public-health experts say.
Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi and Alnylam enter into strategic restructuring of RNAi therapeutics rare disease alliance Restructuring enables streamlined development ...
January 7, 2018 - Sanofi and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today a strategic restructuring of their RNAi therapeutics alliance to streamline and optimize development and commercialization of certain products for the treatment of rare genetic diseases.
In 3Q17, Novo Nordisk’s (NVO) NovoRapid reported revenues of 5.0 billion Danish krone (or DKK), which reflected ~9% growth on year-over-year (or YoY) basis.
In 3Q17, Novo Nordisk’s (NVO) new generation insulin generated revenues of 2.1 billion Danish krone (or DKK), which reflected ~93% growth on a year-over-year (or YoY) basis.
PARIS (Reuters) - France's Sanofi (SASY.PA) said on Thursday it would continue to cooperate with the Philippines' Food and Drug Administration after the country suspended clearance for its controversial ...
MANILA (Reuters) - The Philippines has fined Sanofi $2,000 and suspended clearance for the French drug maker's controversial dengue vaccine Dengvaxia, citing violations on product registration and marketing, ...
As of December 20, 2017, of the three analysts tracking Sanofi ADR, one analyst recommends a “buy,” while two recommend a “hold.”